Drug approved for patients with ALK-positive, early-stage cancer who undergo surgery to remove their tumor
Approval is for tremelimumab in combination with durvalumab and platinum-based chemotherapy
Drug approved for non-small cell lung cancer with mutation leading to MET exon 14 skipping
Lumakras is approved for use in adults with KRAS G12C-mutated non-small cell lung cancer
Cosela reduces the frequency of bone marrow suppression caused by chemotherapy for extensive-stage small cell lung cancer
Current approval of the once-daily tablet indicated for patients who have undergone complete tumor removal